The power of gamma delta T cells

Adicet Bio, Inc. is a biotechnology company developing novel off the shelf T cell therapies to treat cancer. Adicet develops next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Gamma delta T cells perform their tumor-killing function in a MHC-independent manner and thus can be used in an allogeneic setting without the risk of causing Graft vs Host Disease (GvHD). Additionally, gamma delta T cells perform their immune surveillance by naturally homing to various tissues giving them a superior potential to alpha beta T cells to eradicate solid tumors. Adicet has developed a proprietary cell platform process to activate, engineer and expand gamma delta T cells. The process allows for generation of cell banks that can be used to treat many patients.

Leadership:

Investing partner / fund: